Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 3/20 | 0.34 |
| ▸ | PTGFR | P43088 | 8/20 | 0.33 |
| ▸ | PTGER1 | P34995 | 4/20 | 0.33 |
| ▸ | PTGER3 | P43115 | 4/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.32 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.31 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.31 |
| ▸ | SLCO2A1 | Q92959 | 1/20 | 0.31 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.31 |
| ▸ | PTGIR | P43119 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6696130 | 0.92 | PDE4D (0.45) | PDE4DPTGFRPTGER1PTGER3TBXA2R | |
| SCHEMBL6694924 | 0.89 | PDE4D (0.48) | PDE4DPTGFRPTGER1PTGER3TBXA2R | |
| SCHEMBL6691943 | 0.85 | PDE4D (0.39) | PDE4DPTGFRPTGER1PTGER3TBXA2R | |
| SCHEMBL6694952 | 0.83 | PDE4D (0.39) | PDE4DPTGFRPTGER1PTGER3TBXA2R | |
| SCHEMBL6694963 | 0.83 | PDE4D (0.39) | PDE4DPTGFRPTGER1PTGER3TBXA2R | |
| SCHEMBL6694950 | 0.83 | PDE4D (0.39) | PDE4DPTGFRPTGER1PTGER3TBXA2R | |
| SCHEMBL6690354 | 0.82 | PDE4D (0.40) | PDE4DPTGFRPTGER1PTGER3TBXA2R | |
| SCHEMBL8577842 | 0.80 | PDE4D (0.37) | PDE4DPTGFRPTGER1PTGER3TBXA2R | |
| SCHEMBL6694689 | 0.79 | PDE4D (0.30) | PDE4D | |
| SCHEMBL6692631 | 0.79 | PTGFR (0.46) | PTGFRPTGER1PTGER3TBXA2RALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6414022-B2 | POTENT OCULAR HYPOTENSIVES; TREATING GLAUCOMA, INCONTINENCE, IMMUNE REGULATION, BONE METABOLISM DISORDER AND RENAL DYSFUNCTION; ANTIINFLAMMATORY AGENTS | ALLERGAN SALES, INC. | 2002-07-02 | — | — | US | claimed |
| US-20020002150-A1 | Cyclopentane(ENE)heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents | ALLERGAN SALES, INC. | 2002-01-03 | — | — | US | claimed |
| US-20040122102-A1 | Cyclopentane(ENE)heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents | ALLERGAN, INC. | 2004-06-24 | — | — | US | disclosed |
| US-6716876-B2 | ADMINISTERING 7-(5-HYDROXY-2-(HYDROXY- HYDROCARBYL OR HETEROATOM-SUBSTITUTED HYDROXYHYDROCARBYL)-3-HYDROXYCYCLOPENTYL(ENYL)) HEPTANOIC OR HEPTENOIC ACIDS FOR THERAPY OF INCONTINENCE, BONE METABOLISM, RENAL DISORDER | ALLERGAN, INC. | 2004-04-06 | — | — | US | disclosed |
| US-20020143054-A1 | Cyclopentane(ENE)heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents | ALLERGAN, INC. | 2002-10-03 | — | — | US | disclosed |
| US-6414022-B2 | POTENT OCULAR HYPOTENSIVES; TREATING GLAUCOMA, INCONTINENCE, IMMUNE REGULATION, BONE METABOLISM DISORDER AND RENAL DYSFUNCTION; ANTIINFLAMMATORY AGENTS | ALLERGAN SALES, INC. | 2002-07-02 | — | — | US | disclosed |
| US-20020002150-A1 | Cyclopentane(ENE)heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents | ALLERGAN SALES, INC. | 2002-01-03 | — | — | US | disclosed |
| US-6303658-B1 | THERAPY OF OCULAR HYPERTENSION BY APPLYING CYCLOPENTANE HEPTENOIC ACID OR HEPTANOIC ACID AND/OR DERIVATIVE | ALLERGAN SALES, INC. | 2001-10-16 | — | — | US | disclosed |
| US-5990138-A | 7-(5-HYDROXY-2-(HYDROXYHYDROCARBYL OR HETEROATOM-SUBSTITUTED HYDROXYHYDROCARBYL)-3-HYDROXYCYCLOPENTYL(ENYL)) HEPTANOIC OR -ENOIC ACIDS AND DERIVATIVES; POTENT HYPOTENSIVE AGENTS FOR GLAUCOMA; CARDIOVASCULAR, RESPIRATORY DISORDERS; PGS | ALLERGAN (US) | 1999-11-23 | — | — | US | disclosed |
| US-5906989-A | TREATING GLAUCOMA | ALLERGAN SALES, INC. (US) | 1999-05-25 | — | — | US | disclosed |
| EP-0737184-B1 | CYCLOPENTANE(ENE) HEPTENOIC OR HEPTANOIC ACIDS AND DERIVATIVES THEREOF USEFUL AS THERAPEUTIC AGENTS | ALLERGAN INC (US) | 1999-04-28 | — | — | EP | disclosed |
| US-5798378-A | TREATMENT OF OCULAR HYPERTENSION | ALLERGAN (US) | 1998-08-25 | — | — | US | disclosed |
| US-5681848-A | VISION DISORDERS | ALLERGAN (US) | 1997-10-28 | — | — | US | disclosed |
| US-5587391-A | TREATING OCULAR HYPERTENSION | ALLERGAN (US) | 1996-12-24 | — | — | US | disclosed |
| US-5545665-A | GLAUCOMA; REDUCING OCULAR PRESSURE | ALLERGAN (US) | 1996-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122102-A1 | Cyclopentane(ENE)heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents | ELOVL5, SQLE, ALOX5 | PDE4D 1180/4885PTGFR 88/4885PTGER1 16/4885 |
| US-20020002150-A1 | Cyclopentane(ENE)heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents | ELOVL5, SQLE, ALOX5 | PDE4D 1180/4885PTGFR 88/4885PTGER1 16/4885 |
| US-20020143054-A1 | Cyclopentane(ENE)heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents | ELOVL5, SQLE, CYP8B1 | PDE4D 1089/4885PTGFR 92/4885PTGER1 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.